Regulatory Transparency: Forthcoming Lessons from the FDA

被引：0
|
作者：
Chakraborty, Sweta [1 ]
Lofstedt, Ragnar E. [1 ]
机构：
[1] Kings Coll London, London, England
来源：
EUROPEAN JOURNAL OF RISK REGULATION | 2010年 / 1卷 / 02期
关键词：
D O I：
10.1017/SI867299X00000271
中图分类号：
D9 [法律]; DF [法律];
学科分类号：
0301 ;
摘要：
引用
收藏
页码：159 / 162
页数：5
相关论文
共 50 条
  • [21] Lessons From Celect Building Transparency and Trust in Medical Devices
    Kadakia, Kushal T.
    Krumholz, Harlan M.
    Hines, Harold H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (10) : 1038 - 1041
  • [22] Transparency regulation in broadband markets: Lessons from experimental research
    Sluijs, Jasper P.
    Schuett, Florian
    Henze, Bastian
    TELECOMMUNICATIONS POLICY, 2011, 35 (07) : 592 - 602
  • [23] Transparency in eVoting Lessons learnt
    Prosser, Alexander
    TRANSFORMING GOVERNMENT- PEOPLE PROCESS AND POLICY, 2014, 8 (02) : 171 - 184
  • [24] Commentary: Data monitoring confidentiality and FDA transparency
    London, Alex John
    CLINICAL TRIALS, 2015, 12 (01) : 12 - 14
  • [25] The FDA, Juno Therapeutics, and the ethical imperative of transparency
    Hey, Spencer Phillips
    Kesselheim, Aaron S.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [26] REMARKS ON REGULATORY PHILOSOPHY OF FDA
    HAGAN, CF
    FOOD AND DRUG LAW JOURNAL, 1973, 26 (03): : 195 - 200
  • [27] FDA seeks regulatory flexibility
    Wechsler, Jill
    Pharmaceutical Technology, 2008, 32 (03) : 36 - 44
  • [28] Navigating the FDA regulatory landscape
    Scott, Pamela D.
    Bajaj, Anita
    McMullen, David P.
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 (01) : 18 - 22
  • [29] FDA regulatory compliance reconsidered
    Tobias, Carl
    CORNELL LAW REVIEW, 2008, 93 (05) : 1003 - 1038
  • [30] FDA MODEL FOR REGULATORY PURPOSES
    STRATMEYER, ME
    ULTRASOUND IN MEDICINE AND BIOLOGY, 1989, 15 : 35 - 36
12345